EGFR and non-small cell lung carcinoma: Mobocertinib is a novel small-molecule TKI designed against exon 20 insertions; in a phase I/II clinical trial, mobocertinib showed promising antitumor activity in previously treated NSCLC patients with EGFR exon 20 insertions, resulting in “breakthrough therapy designation” by the U.S. Food and Drug Administration (FDA) [76,77].